David Kirn, 4DMT CEO
August 9, 2024 09:59 AM EDT
R&D
Cell/Gene Tx
FDA+

FDA lifts hold on 4DMT's Fab­ry gene ther­a­py

Kyle LaHucik

Senior Reporter

The FDA lift­ed an 18-month clin­i­cal hold on 4D Mol­e­c­u­lar Ther­a­peu­tics’ car­diomy­opa­thy gene ther­a­py for Fab­ry dis­ease.

The biotech said Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

ADC sci­en­tist who paved the way for Dai­ichi’s En­her­tu dies

As­traZeneca re­veals first clin­i­cal da­ta for bis­pe­cif­ic T cell en­gager from TeneoT­wo buy­out

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Biose­cure bill is left out of end-of-year de­fense pack­age, deal­ing blow to chances

Dutch biotech nabs €85M to po­si­tion in­flam­ma­to­ry an­ti­body for a phar­ma buy­er

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times